Clinical milestones and earnings set the context for Compass Therapeutics stock

Compass Therapeutics (CMPX) has been in focus after reaching the planned survival event threshold in its Phase 2/3 COMPANION-002 trial for biliary tract cancer, along with FDA clearance for its CTX-10726 investigational program.

These developments come as the company reported a full year 2025 net loss of US$66.49 million and a fourth quarter net loss of US$15.72 million, figures that help frame current expectations around the stock.

Against this backdrop, Compass Therapeutics’ 1-month share price return of a 12.95% decline contrasts with a year to date share price return of 6.58% and a 1-year total shareholder return of 104.83%, suggesting strong longer term momentum despite recent softness.

If these clinical updates have you watching biotech more closely, it could be a good moment to see what else is moving in healthcare related AI through our 32 healthcare AI stocks.

With the shares trading at US$5.51, a reported intrinsic discount of 86% and a price target gap of more than double, you have to ask: is Compass Therapeutics on sale, or is the market already factoring in future growth?

Price to book of 5x, is it justified?

On our data, Compass Therapeutics trades on a P/B of 5x compared with 2.6x for the broader US Biotechs group, so the shares sit at a clear premium to the sector while still changing hands at $5.51.

The P/B ratio compares the share price with the company’s net assets on the balance sheet. For a clinical stage biotech with no meaningful revenue and ongoing losses, a higher P/B often reflects what the market currently assigns to the pipeline, intellectual property and future optionality rather than today’s earnings power.

Here, CMPX screens as expensive versus the wider US Biotechs average on that simple P/B check, yet looks more in line with its closer peer set given the peer average P/B of 5.8x. In other words, the broader sector comparison suggests the market is paying up relative to typical biotech balance sheets. However, the peer comparison indicates pricing that sits closer to what investors are currently paying for companies with a similar profile and stage of development.

Result: Price to book of 5x (ABOUT RIGHT)

However, the story can change quickly if key trials disappoint or if continued net losses of US$66.49 million begin to pressure funding options.

Another view using our DCF model

While CMPX looks expensive on a 5x P/B against the broader US Biotechs group, our DCF model points in a different direction, with an estimated future cash flow value of $41.25 per share versus a market price of $5.51. That gap suggests investors are pricing trial risk heavily, but it raises the question of whether sentiment is overshooting the fundamentals.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Compass Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Does this feel like a mix of promise and risk to you as well? If so, take a closer look at the key factors and form your own view, starting with 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If CMPX has sparked your curiosity, do not stop here. Use this momentum to broaden your watchlist with other focused ideas that match your style.

• Target opportunities that combine quality with a potential discount by reviewing our list of 50 high quality undervalued stocks that pass fundamental checks.
• Strengthen your income focus by checking out 16 dividend fortresses, a set of companies with yields above 5% that could suit investors who prioritize regular cash returns.
• Reduce guesswork around financial resilience by scanning solid balance sheet and fundamentals stocks screener (41 results), which highlights companies with balance sheets and fundamentals that might better handle pressure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.